Bioxcel therapeutics announces pricing of public offering of common stock

New haven, conn., june 23, 2021 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public offering price of $31.70 per share. in addition, a related party stockholder, bioxcel llc, has granted the underwriters a 30-day option to purchase up to an additional 473,250 shares of common stock at the public offering price, less underwriting discounts and commissions. gross proceeds to the company from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses. the company will not receive any of the proceeds from any sale of shares in this offering by bioxcel llc.
BTAI Ratings Summary
BTAI Quant Ranking